Ladies and gentlemen, thank you for standing by, and welcome to the Kyverna Therapeutics, Inc. Annual Meeting. I'll now turn the conference over to Warner Biddle. You may begin. Thank you. Good morning, ladies and gentlemen. Welcome to the 2026 Annual Meeting of Stockholders of Kyverna Therapeutics. I'm Warner Biddle, the company's Chief Executive Officer. 2026 marks a pivotal inflection year for Kyverna as we transition to a commercial stage company, supported by strong clinical execution and significant regulatory progress. We've delivered transformative data in stiff person syndrome and generalized myasthenia gravis, which continue to demonstrate mivocabtagene's potential to change the treatment paradigm by delivering durable, drug-free, disease-free remissions for patients. Importantly, we recently gained regulatory alignment with the FDA on a clear path forward for mivocabtagene and stiff person syndrome. As we execute on our rolling BLA submission and prepare for the potential commercial launch of the first approved CAR T-cell therapy in autoimmune diseases, we are excited to lay the foundation for a multi-indication neuroimmunology franchise that reinforces our leadership position in this space. On behalf of the board and the entire company, I would like to thank you for your continued support in our mission to liberate autoimmune patients through the curative potential of cell therapy. At this time, I call the meeting to order. The company's board of directors has appointed me to act as Chairman of this meeting. Greg Martini, the company's Chief Financial Officer, will act as Secretary of this meeting. I would also like to introduce Bo Monaco, a Partner of BDO USA, our independent registered public accounting firm. Ms. Monaco will be available to answer any appropriate questions you may have concerning the independent audit. The board of directors has appointed John Holowach of Broadridge Financial Solutions to act as Inspector of Election for this meeting. Mr. Holowach has previously taken his oath as Inspector of Election. He will file the executed oath with the records of this meeting. If you have already voted by proxy, you do not need to take any further action. If you wish to vote during this meeting, please log in to the web portal as a stockholder by entering the 16-digit control number you received with your proxy materials and clicking on the voting button in the web portal and following the instructions there. The secretary will now review the agenda, rules of conduct, and procedures for today's meeting and present the affidavit of mailing of the notice of availability of proxy materials. Thank you, Warner. Today's agenda and a link to the rules of conduct and procedures for the meeting can be found in the Meeting Materials section on the web portal. To conduct an orderly meeting, we ask that participants abide by these rules. As stated in the rules of conduct, only validated stockholders may ask questions in the designated field on the web portal, and we ask that you restrict your questions to the agenda items that are before us. Thank you for your cooperation with these rules. There are two items of business on today's agenda. The election of two Class II directors and the vote on the ratification of the appointment of the company's independent registered public accounting firm and independent auditor. Each of these items is described in the proxy statement for this meeting. The board of directors set March 30th, 2026, as the date of record for this meeting. We have at this meeting a recording of stockholders as of that date. A duplicate record has been on file at the principal place of business of the company for the last 10 days and has been available for inspection by any stockholder during normal business hours during that period. Mr. Chairman, I present the affidavit of mailing from Broadridge Financial Solutions, which states that the notice of availability of proxy materials was mailed on April 13th, 2026, to stockholders of record as of the close of business on March 30th, 2026, the record date for stockholders entitled to notice of this meeting, which is in accordance with the bylaws of the company. Thank you, Greg. I direct that the affidavit of mailing be made part of the minutes of this meeting. Our first order of business at this meeting is to determine whether the shares represented at the meeting are sufficient to constitute a quorum for the purposes of transacting business. Greg, do you have a report? Yes. I have been advised by the inspector of election that approximately 73% of issued and outstanding shares of the company's common stock is represented at today's meeting, which is sufficient to constitute a quorum for the purpose of transacting business at this meeting. Thank you, Greg. The report of the secretary on the existence of a quorum is accepted. Since a majority of the company's issued and outstanding shares of common stock is represented here today, I declare that a quorum is present and the meeting is duly constituted. It is 11:05 A.M. Pacific Time, and the polls are now open for voting. If you wish to vote at the meeting, whether or not you've already submitted a proxy, then you may vote by clicking on the voting buttons in the web portal and following the instructions there. You will be able to vote any time from now through the presentation of the proposals until the polls are closed. No ballots or proxies or revocations or changes of proxies will be accepted after the polls are closed. Any stockholder who has previously given their proxy need not vote unless the stockholder desires to revoke the proxy and vote by electronic ballot at this meeting. We may now proceed to transact the business for which this meeting has been called. A description of the matters properly brought before this meeting and the required votes for such proposals are described in the proxy statement for this meeting. The first proposal is for the election of two directors, each to serve as Class II directors until 2029 Annual Meeting of Stockholders or until such director's respective successor is duly elected and qualified. The board of directors has nominated and recommends a vote for Ian Clark and Christi Shaw, both current directors of the company. The company's bylaws require that a stockholder provide advance notice to the company of a stockholder's intent to nominate a person as directors. No such notice was received, and accordingly, I declare the nominations for the directors closed. The second matter being submitted to the stockholders for action is the ratification of the appointment of BDO USA as the company's independent registered public accounting firm and the independent auditor for the year ending December 31st, 2026. Since the company did not receive any other stockholder proposal for this year's annual meeting, we will proceed to the voting. I directed a vote for the stockholders be taken by electronic ballot on the matters previously described. Voting is by proxy and electronic ballot. If you wish to vote now, whether or not you've already submitted a proxy, then you may now vote by clicking on the voting button in the web portal and following the instructions there. Each holder of common stock is entitled to one vote for each share held of record at the close of business on March 30th, 2026. Any stockholder who's previously given their proxy need not vote unless the stockholder desires to revoke the proxy and vote by electronic ballot at this meeting. I declare the polls for each matter voted upon at this meeting now closed at 11:08 A.M. Pacific Time today and direct the inspector of election to tabulate the ballots. Will the secretary please report the preliminary results of the voting? Yes. Although all the numbers on the share vote are not in, I can provide the following preliminary results from the inspector of election. I have been advised by the inspector of election that Mr. Clark and Ms. Shaw have each been elected as Class II directors of the company, each to serve for the term expiring on the date of the company's 2029 annual meeting of stockholders, or until such director's respective successor has been duly elected and qualified. I have been further advised by the inspector of election that the ratification of the appointment of BDO as the company's independent registered public accounting firm and independent auditor for the year ending December 31st, 2026, has been approved. The inspector of election has indicated that he will furnish me with a written report of the final vote count with respect to matters voted on today. A final tally of the votes will be published in a current report on Form 8-K filed with the Securities and Exchange Commission on or before June 2nd, 2026. Thank you, Greg. Please include the inspector of election's written report of the final vote count in the minutes for today's meeting. There being no further business to come before the meeting, the 2026 annual meeting of stockholders of Kyverna Therapeutics is now adjourned. We note that we have not received any questions regarding the agenda items during the meeting today. Therefore, we will end today's meeting. I would like to say thank you to everyone for attending today's meeting and for your continuing support of Kyverna Therapeutics. Thank you. This concludes today's annual meeting. You may now disconnect.